CRISPR Therapeutics (NASDAQ:CRSP) Given New $47.00 Price Target at The Goldman Sachs Group
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by equities research analysts at The Goldman Sachs Group from $53.00 to $47.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 31.95% […]
More Stories
DOJ Says It May Drop Boeing Criminal Fraud Case Over 737 Max Crashes
By Bill Pan The U.S. Department of Justice (DOJ) said it may drop its criminal prosecution of Boeing over allegations...
Milk, Science, and School Lunches: A Battle Over What Kids Eat
By Sherami Tsai Lawmakers are pushing to bring whole milk back to school cafeterias after it was banned in 2012. ...
Top Casino Stocks To Add to Your Watchlist – May 17th
Flutter Entertainment, DraftKings, Wynn Resorts, MGM Resorts International, and Churchill Downs are the five Casino stocks to watch today, according...
Focus Partners Wealth Grows Stock Position in Invesco Ltd. (NYSE:IVZ)
Focus Partners Wealth boosted its stake in shares of Invesco Ltd. (NYSE:IVZ – Free Report) by 66.8% during the 4th...
Janus Henderson Group PLC Has $3.43 Million Stock Holdings in H&R Block, Inc. (NYSE:HRB)
Janus Henderson Group PLC lifted its holdings in H&R Block, Inc. (NYSE:HRB – Free Report) by 3.2% in the 4th...
Focus Partners Wealth Buys Shares of 4,469 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
Focus Partners Wealth bought a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) in the 4th quarter, according...